UNSPSC 51422112: Clocortolone pivalate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H36ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QBL8IZH14X, chemically known as 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-pivalate but more generally known as clocortolone pivalate, which bears US NIH Compound Identifier 36673. European Medicines Agency schedules Clocortolone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13393MIG.

UNSPSC 51422112 Clocortolone pivalate is a Commodity code that nominally designates a topical corticosteroid pharmaceutical product, but the recent state and local opportunities tagged under this code show little alignment with that scope. The two posted opportunities involve naloxone procurement and direct-to-manufacturer prescription program design — neither of which relates to clocortolone pivalate or its therapeutic class. State and local governments appear to use this code inconsistently or the opportunities are mislabeled in the underlying source data. No recent state and local solicitations for clocortolone pivalate itself are evident.

The two opportunities present in the record span different issuing bodies and procurement mechanisms but do not substantiate activity under the code's nominal pharmaceutical scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the due date appears to be a data entry error given the posted date of June 30, 2026). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, with no formal competitive evaluation or award value specified at the exploratory information-gathering phase. Both opportunities involve pharmaceutical or pharmacy benefit program services but neither targets clocortolone pivalate specifically. The code shows no relevant recent activity for business development purposes.